Drug trial tests hope for controlling rare, spreading eye cancer
NCT ID NCT02517736
Summary
This study tested whether the drug sorafenib could help control the spread of cancer in adults with uveal melanoma that had spread to other parts of the body. It involved 32 participants and measured if the cancer stopped growing for at least 24 weeks while on the treatment. The trial also closely monitored the side effects and safety of the drug.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UVEAL MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Service d'ophtalmologie, CHU de Caen
Caen, 14000, France
Conditions
Explore the condition pages connected to this study.